Mevius Antje, Lutter Johanna, Karl Florian M, Tuffy Liam, Schochter Fabienne, Fuchs Andreas, Wilke Thomas
IPAM e.V., University of Wismar, Wismar, Germany.
GSK, Munich, Germany.
Oncol Res Treat. 2025;48(3):92-101. doi: 10.1159/000542773. Epub 2024 Nov 27.
The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 and 2021.
In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset from a regional health insurance fund in the German states of Saxony and Thuringia. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period.
The incidence of primary advanced or recurrent endometrial cancer in 2021 was 4.77 cases/100,000 persons, with no substantial change over time (4.63 in 2018; 4.93 in 2019; 4.45 in 2020). The point prevalence on 1 January 2022 was 0.023%, with a slight increase in prevalence observed from 1 January 2019 onwards. Among 466 patients with confirmed endometrial cancer, the mean (standard deviation) age was 68.0 (11.6) years; the tumor material from 86 patients (18.5%) underwent immunohistochemistry or polymerase chain reaction testing. Median overall survival was estimated to be 47.5 months (95% CI: 35.1-70.4) and the 5-year survival probability was 46.2%. The most frequent first-line systemic therapies were carboplatin (45.7%) and paclitaxel (43.1%). Second-line therapy was received by 153 patients (32.8%).
The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.
The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 and 2021.
In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset from a regional health insurance fund in the German states of Saxony and Thuringia. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period.
The incidence of primary advanced or recurrent endometrial cancer in 2021 was 4.77 cases/100,000 persons, with no substantial change over time (4.63 in 2018; 4.93 in 2019; 4.45 in 2020). The point prevalence on 1 January 2022 was 0.023%, with a slight increase in prevalence observed from 1 January 2019 onwards. Among 466 patients with confirmed endometrial cancer, the mean (standard deviation) age was 68.0 (11.6) years; the tumor material from 86 patients (18.5%) underwent immunohistochemistry or polymerase chain reaction testing. Median overall survival was estimated to be 47.5 months (95% CI: 35.1-70.4) and the 5-year survival probability was 46.2%. The most frequent first-line systemic therapies were carboplatin (45.7%) and paclitaxel (43.1%). Second-line therapy was received by 153 patients (32.8%).
The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.
本研究旨在描述原发性晚期或复发性子宫内膜癌的流行病学情况，以及2015年至2021年期间德国受影响患者的实际治疗模式的结果。
在这项回顾性队列研究中，研究期间为2015年1月1日至2021年12月31日，从德国萨克森州和图林根州一家地区健康保险基金的匿名理赔数据集中提取了原发性晚期或复发性子宫内膜癌并开始接受全身治疗的患者数据。流行病学结果为子宫内膜癌的累积发病率和点患病率。评估索引日期后的总生存期，将全因死亡作为事件。描述了索引日期后与子宫内膜癌相关的实际治疗模式。
2021年原发性晚期或复发性子宫内膜癌的发病率为4.77例/10万人，随时间无显著变化（2018年为4.63例/10万人；2019年为4.93例/10万人；2020年为4.45例/10万人）。2022年1月1日的点患病率为0.023%，自2019年1月1日起患病率略有上升。在466例确诊为子宫内膜癌的患者中，平均（标准差）年龄为68.0（11.6）岁；86例患者（18.5%）的肿瘤组织进行了免疫组织化学或聚合酶链反应检测。估计中位总生存期为47.5个月（95%置信区间：35.1 - 70.4），5年生存概率为46.2%。最常用的一线全身治疗药物是卡铂（45.7%）和紫杉醇（43.1%）。153例患者（32.8%）接受了二线治疗。
对德国理赔数据的分析得出了晚期或复发性子宫内膜癌的当代流行病学估计。在研究期间，治疗与指南建议一致，肿瘤检测尚未进入主流实践。
本研究旨在描述原发性晚期或复发性子宫内膜癌的流行病学情况，以及2015年至2021年期间德国受影响患者的实际治疗模式的结果。
在这项回顾性队列研究中，研究期间为2015年1月1日至2021年12月31日，从德国萨克森州和图林根州一家地区健康保险基金的匿名理赔数据集中提取了原发性晚期或复发性子宫内膜癌并开始接受全身治疗的患者数据。流行病学结果为子宫内膜癌的累积发病率和点患病率。评估索引日期后的总生存期，将全因死亡作为事件。描述了索引日期后与子宫内膜癌相关的实际治疗模式。
2021年原发性晚期或复发性子宫内膜癌的发病率为4.77例/10万人，随时间无显著变化（2018年为4.63例/10万人；2019年为4.93例/10万人；2020年为4.45例/10万人）。2022年1月1日的点患病率为0.023%，自2019年1月1日起患病率略有上升。在466例确诊为子宫内膜癌的患者中，平均（标准差）年龄为68.0（11.6）岁；86例患者（18.5%）的肿瘤组织进行了免疫组织化学或聚合酶链反应检测。估计中位总生存期为47.5个月（95%置信区间：35.1 - 70.4），5年生存概率为46.2%。最常用的一线全身治疗药物是卡铂（45.7%）和紫杉醇（43.1%）。153例患者（32.8%）接受了二线治疗。
对德国理赔数据的分析得出了晚期或复发性子宫内膜癌的当代流行病学估计。在研究期间，治疗与指南建议一致，肿瘤检测尚未进入主流实践。
